Bloomberg News

FDA Has Concerns About Study of Atricure for Irregular Heartbeat

October 24, 2011

Oct. 24 (Bloomberg) -- U.S. regulators said they’re concerned about a study on AtriCure Inc.’s alternative during open-heart surgery to treat an irregular heartbeat.

The device system from the West Chester, Ohio-based company to destroy heart tissue during surgery is set to be considered by a Food and Drug Administration advisory panel on Oct. 26.

To contact the reporter on this story: Anna Edney in Washington at aedney@bloomberg.net

To contact the editor responsible for this story: Adriel Bettelheim at abettelheim@bloomberg.net


Race, Class, and the Future of Ferguson
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus